SWOG clinical trial number
SWOG-8991 (EST-3588) (RTOG-8815) (INT-0096)

A Phase III Study of Cisplatin plus Etoposide Combined with Standard Fractionation Thoracic Radiotherapy vs Cisplatin plus Etoposide Combined with Multiple Daily Fractionated Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer

Closed
Phase
Published
Abbreviated Title
A Phase III Study of Cisplatin plus Etoposide Combined with Standard Fractionation Thoracic Radiotherapy vs Cisplatin plus Etoposide Combined with Multiple Daily Fractionated Thoracic Radiotherapy…
Activated
02/15/1990
Closed
08/01/1992

Research committees

Lung Cancer

Publication Information Expand/Collapse

1999

Twice-daily compared with once-daily thoracic radiotherapy in limited small cell lung cancer treated concurrently with cisplatin and etoposide

AT Turrisi;K Kim;R Blum;WT Sause;RB Livingston;R Komaki;H Wagner;S Aisner;DH Johnson New England Journal of Medicine 340(4):265-271

1998

Observations after 5 year follow-up of intergroup trial 0096: 4 cycles of cisplatin(P) etoposide (E) and concurrent 45 GY thoracic radiotherapy (TRT) given in daily (QD) or twice-daily fractions followed by 25 GY PCI. Survival differencs and patterns of failure.

A Turrisi;K Kim;W Sause;R Komaki;H Wagner;S Aisner;R Livingston;R Blum;D Johnson Proc of the American Society of Clinical Oncology 17:457a(#1757

Incidence and clinical significance of variant morphology (small cell/large cell subtype) in limited stage small cell lung cancer (SCLC). A prospective analysis of an intergroup ECOG, RTOG and SWOG study.

SC Aisner;A Turrisi;KM Kim;WT Sause;RB Livingston;L Einhorn;H Wagner;D Ettinger;R Komaki;R Blum;DH Johnson Proc of the American Society of Clinical Oncology 17:458a(#1764)

Other Clinical Trials

SWOG Clinical Trial Number
S2409

PRISM: PRecIsion in SCLC via a Multicohort Study: Randomized Phase II studies evaluating maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Research Committee(s)
Lung Cancer
Activated
09/08/2025
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA5231

A Randomized Phase III Trial of Checkpoint Blockade in Lung Cance3r Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR)
Research Committee(s)
Lung Cancer
Activated
06/13/2025
Open
Phase
SWOG Clinical Trial Number
S2414

INcorporating pathologic reSponse in patIents with early staGe lung cancer to optimize immunotHerapy in the adjuvanT setting (INSIGHT)
Research Committee(s)
Lung Cancer
Symptom Management and Survivorship
Activated
03/14/2025
Accrual
2%
Open
Phase